The document defines several medical abbreviations and terms related to hypertension and blood pressure measurement. It provides guidelines from sources like JNC 7 and WHO for stages of hypertension based on systolic and diastolic blood pressure levels. Tables show target blood pressure levels according to age and risk factors. Lifestyle modifications like weight loss, dietary changes, and physical activity are recommended as first-line treatment, along with medications like ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics.

2. Angiotensin converting enzyme inhibitor ACEI
Angiotensin receptor blocker ARB
Body mass index BMI
Calcium channel blocker CCB
Coronary heart disease CHD
Dietary approach to stop hypertension DASH
Diastolic blood pressure DBP
High-density lipoprotein cholesterol HDL-C
Low-density lipoprotein cholesterol LDL-C
Monoamine oxidase MAO
Nonsteroid anti-inflammatory drug NSAID
Systolic blood pressure SBP
The Seventh Report of the Joint National Committee JNC 7
on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure
Total cholesterol TC
Triglyceride TG
Aldosterone antagonist
Ambulatory blood pressure monitoring
Aneurysm
Antecubital fossa
Angioedema
Angiotensin converting enzyme inhibitor (ACEI)
Angiotensin receptor blocker (ARB)
Autonomic dysfunction
Bioavailability
Body mass index (BMI)
Brachial pulse
-agonist
-blocker
Catecholamine
1

3. Calcium channel blocker (CCB)
Coronary heart disease (CHD)
Corticotropin (ACTH)
Conn's syndrome
Cyclosporine
Diastolic blood pressure (DBP)
Dietary approach to stop hypertension (DASH) trial
Doppler
Dopamine
Ductus arteriosus
Erythropoietin (EPO)
Episodic hypertension
Epinephrine
First dose effect
Framingham study
High-density lipoprotein cholesterol (HDL-C)
Intrinsic sympathomimetic effect
Isolated systolic hypertension
Licorice
Low-density lipoprotein cholesterol (LDL-C)
Microalbuminuria
Mineralocorticosteroid
Monoamine oxidase (MAO) inhibitors
Nonsteroid anti-inflammatory drug (NSAID)
Norepinephrine
Phase 1
Phase 5
Prehypertension
Renin
Systolic blood pressure (SBP)
Target organ
Total cholesterol (TC)
Triglyceride (TG)
Tyramine
White-coat hypertension
Withdrawal syndrome
2

4. -
WHO ISH
Guideline,1999
7 JNC7 2003
3

5. 2002
15 24.9% 18.2% 65
56.6%
40% 25% 50%
2002
59% 79%
47% 64% 21%
29%
4

6. contents
contents
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
. . . . . . . . . . . . . . . . . . . . . . .10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16
. . . . . . . . . . . . . . . . . . . . . . . . . . . .21
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .24
. . . . . . . . . . . . . . . . . . . . . . . . .38
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .56
. . . . . . . . . . . . . . . . . . . . . . . . . . .74
.87
. . . . . . . . . . . . . . . . . . . . . . . . . . . .90
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .91
5

7. 147.7
156.8 1-1
152.9
152.3
1-1
6

8. 40% 25% 50%
(1)
(2)
(3)
(4)
(5) angiotensin
receptor blocker
(6) (The Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure, the JNC 7)
(1999 World Health Organization-International Society of
Hypertension Guidelines for the Management of Hypertension
& ESH Updates)
7

9. (1)
120/80 mmHg 130/85
mmHg 120 139 mmHg 80 89 mmHg
(2)
115/75 mmHg
20/10 mmHg
(3) ( 140 mmHg)
(4) DASH
(5)
thiazide
(6)
8

10. 140/90 mmHg
130/80 mmHg
20/10 mmHg
thiazide
(1)
(2)
(3)
9

11. JNC 7 2003
140 mmHg / (diastolic
blood pressure, DBP) 90 mmHg
120 mmHg 80 mmHg
prehypertension 2-1 JNC 7
140-159 mmHg
/ 90-99 mmHg
160 mmHg / 100 mmHg
2-1 18
(mmHg) (mmHg)
<120 <80
(prehypertension) 120-139 80-89
140-159 90-99
160 100
95 2-2
10

12. 2-2
( 90-94 ) ( 95-99 ) ( 99 )
(SBP)
7 96-105 106
8-30 104-109 110
2
SBP 104-111 112-117 118
DBP 70-73 74-81 82
3-5
SBP 108-115 116-123 124
DBP 70-75 76-83 84
6-9
SBP 114-121 122-129 130
DBP 74-77 78-85 86
10-12
SBP 122-125 126-133 134
DBP 78-81 82-89 90
13-15
SBP 130-135 136-143 144
DBP 80-85 86-91 92
16-18
SBP 136-141 142-149 150
DBP 84-91 92-97 98
Systolic blood pressure, SBP Diastolic blood
pressure, DBP mmHg
11

13. 210/120 mmHg
10
23
2-1
120/80 mmHg
JNC 7
115/75
mmHg 20 mmHg 10
mmHg
12

14. 2-1
96%
JNC 7 5000
10
1993-1996
26% 19%
2002 15
24.9% 18.2%
2002 18 30 30
60
2-2
13

15. 30 60 2-
3
1989-1991 65
36.9
2002 65
56.6%
40
60
2002 60
60 2-4
1990
1993-1996
46
14

16. 2-2 15
2002
2-3 15
2002
2-4 15
<20 20-29 30-39 40-49 50-59 60-69 70-79 80+
2002
15

17. 140 mmHg 90 mmHg
( 120-139 mmHg
80-89 mmHg)
( )
16

18. 3-1
(cuff) 12.5
( 3-1) (inner bag)
80%
3-1
1 2.5
1-3 5-6
4-8 9-10
12.5
14
3-1
17

19. ( 2
)
(antecubital fossa)
(brachial pulse)( 3-2)
20~30 mmHg 2~3 mmHg
(phase 1 )
(phase 5 )
Nicolai S. Korotkoff 1905
(muffling )
2~3
5 mmHg
18

20. 3-2
21
( 210 mmHg 120 mmHg)
3-2
3-2 18 *
(mmHg) *
< 120 < 80
120 - 139 80 - 89
140 - 159 90 - 99
160 - 179 100 - 109
≥180 ≥110
*
19

21. (ambulatory blood
pressure monitoring) 3-3
3-3
10-
20%
white-coat hypertension
episodic hypertension
autonomic dysfunction
135/85 mmHg
20

22. 115/75 mmHg 185/115 mmHg 20 mmHg
10 mmHg
140-159 mmHg 90-99 mmHg
12 mmHg
Framingham Study
50 140
mmHg
isolated systolic hypertension
coronary heart disease, CHD
CHD
CHD CHD
21

23. 5 mmHg
140/90
mmHg
1999-2000 JNC 7
1993 1996
43% 53%
31% 45%
22

24. 15% 22% 2002
59% 79%
47% 64% 21%
29%
23

25. 96 99
5-1
24

26. 1
2
3
4
1.
2.
14
25

27. 5 2.5
6 2.4
3.
4.
5.
6.
26

28. 5-1
1.
2.
(A)
(B) (C)
(1)
30 g
27

29. 15 mmHg
7 10 mmHg
(2) (licorice) carbenoxolone (
)
(mineralocorticosteroid)
(3) (corticotropin, ACTH)
(4) (nonsteroid anti-inflammatory drug,
NSAID) indomethacin
(5) phenylpropanolamine
(catecholamine)
(MAO inhibitor) pargyline
(tyramine)
3.
28

30. 4.
ductus arteriosus
5.
Conn's syndrome
29

31. ()
()
() (target organ) ( 5-2)
5-2 (target organ)
50%
aneurysm
1.5 mg/dL
1(+)
microalbuminuria
30

32. (cyclosporine) (erythropoietin, EPO)
(MAO inhibitor)
31

33. 1.
2.
32

34. 3.
5-3
33

35. 5-3
(1)
(2)
X
(3)
(catecholamine)
1.
34

36. (1)
Sokolow-Lyon V5 V6
R V1 S 35 (mV)
(2)
(3)
(4)
(5)
35

37. (6)
(7)
(8)
2.
3.
(1)
(Doppler)
36

38. (2)
(renin)
24 (catecholamine)
(norepinephrine)
(epinephrine) (dopamine)
37

39. 2003 JNC 7
6-1
6-1 *
(BMI1 18.5 23.9) 10
5 20 mmHg
DASH2
8 10 mmHg
2.4 g 2 8 mmHg
( 6g )
4 9 mmHg
3 30
30cc 2 4 mmHg
15
cc(30cc 720cc
300 cc 60cc )
)
*
BMI [ ( )]/[ ( )] 2
1
DASH Dietary Approach to Stop Hypertension,
2
2100 /
38

40. (body mass index, BMI)
BMI
BMI 18.5~23.9
18.5 24 27
30 35 BMI 30
BMI
BMI
BMI 6-2.1 6-2.2
6-2.1 BMI
( )
BMI (Body Mass Index) 2
( )
( )2 22
( 10% )
90
80
39

41. 6-2.2 (BMI)
( )
150 41.6 41.6 54.0 54.0 60.8 67.5 78.8
151 42.2 42.2 54.7 54.7 61.6 68.4 79.8
152 42.7 42.7 55.4 55.4 62.4 69.3 80.9
153 43.3 43.3 56.2 56.2 63.2 70.2 82.0
154 43.9 43.9 56.9 56.9 64.0 71.1 83.0
155 44.4 44.4 57.7 57.7 64.9 72.1 84.1
156 45.0 45.0 58.4 58.4 65.7 73.0 85.2
157 45.6 45.6 59.2 59.2 66.6 73.9 86.3
158 46.2 46.2 59.9 59.9 67.4 74.9 87.4
159 46.8 46.8 60.7 60.7 68.3 75.8 88.5
160 47.4 47.4 61.4 61.4 69.1 76.8 89.6
161 48.0 48.0 62.2 62.2 70.0 77.8 90.7
162 48.6 48.6 63.0 63.0 70.9 78.7 91.9
163 49.2 49.2 63.8 63.8 71.7 79.7 93.0
164 49.8 49.8 64.6 64.6 72.6 80.7 94.1
165 50.4 50.4 65.3 65.3 73.5 81.7 95.3
166 51.0 51.0 66.1 66.1 74.4 82.7 96.4
40

42. 167 51.6 51.6 66.9 66.9 75.3 83.7 97.6
168 52.2 52.2 67.7 67.7 76.2 84.7 98.8
169 52.8 52.8 68.5 68.5 77.1 85.7 100.0
170 53.5 53.5 69.4 69.4 78.0 86.7 101.2
171 54.1 54.1 70.2 70.2 79.0 87.7 102.3
172 54.7 54.7 71.0 71.0 79.9 88.8 103.5
173 55.4 55.4 71.8 71.8 80.8 89.8 104.8
174 56.0 56.0 72.7 72.7 81.7 90.8 106.0
175 56.7 56.7 73.5 73.5 82.7 91.9 107.2
176 57.3 57.3 74.3 74.3 83.6 92.9 108.4
177 58.0 58.0 75.2 75.2 84.6 94.0 109.7
178 58.6 58.6 76.0 76.0 85.5 95.1 110.9
179 59.3 59.3 76.9 76.9 86.5 96.1 112.1
180 59.9 59.9 77.8 77.8 87.5 97.2 113.4
181 60.6 60.6 78.6 78.6 88.5 98.3 114.7
182 61.3 61.3 79.5 79.5 89.4 99.4 115.9
183 62.0 62.0 80.4 80.4 90.4 100.5 117.2
184 62.6 62.6 81.3 81.3 91.4 101.6 118.5
185 63.3 63.3 82.1 82.1 92.4 102.7 119.8
41

43. BMI
10%
Dietary Approach to Stop Hypertension trial, DASH trial 1997
2
6
DASH 6-3
DASH
6-4
42

44. 6-3 DASH
* DASH
DASH
1. /
1.6 5.2
2.0 4.4
8.2 7.5
0.1 2.0
0.4 0.7
0 0.7
1.5 0.5
0.8 0.6
0.2 0.5
5.8 2.5
4.1 0.7
2.
37 27
16 6
13 13
8 8
48 55
15 18
/ 300 150
/ 19 31
/ 1700 4700
/ 165 500
/ 450 1240
/ 3000 3000
* 2100
43

45. 6-4 DASH
7-8 1
4-5 1
6 oz
4-5 6 oz
1
1/4
2-3 8 oz 1 1%
1.5 oz
2 3 oz
1-2 1.5 oz 1/3 2
DASH
44

46. 10 mmHg
6-5
6-6 6-7 6-8
6-5
100 100
( )( ) ( )( )
111 2.8 256 6.6
135 3.5 270 6.9
142 3.6 274 7.0
151 3.9 279 7.2
154 3.9 293 7.5
166 4.2 322 8.2
196 5.0 326 8.4
203 5.2 349 8.9
221 5.7 350 9.0
221 5.7 398 10.2
222 5.7 416 10.7
228 5.8 420 10.8
234 6.0 461 11.8
235 6.0 469 12.0
238 6.0 546 14.0
245 6.3 () 1482 38.0
A 254 6.5 193 4.9
65 1.5 207 5.3
() 102 2.6 214 5.5
111 2.8 221 5.7
() 112 2.9 245 6.3
125 3.2 291 7.5
130 3.3 315 8.1
135 3.5 323 8.3
167 4.3 401 10.3
170 4.4 495 12.7
176 4.5 536 13.7
181 4.6
45

47. 6-6
( /100 )
50 100
101 200
()
201 300
301 400
400
()
6-7
( ) 599 250
445 238
( ) 444 231
434 230
418 219
379 189
46

48. 318 177
294 169
283 () 163
281 162
280 153
250
6-8
/100
100.0 32.5 45.4 17.6
100.0 39.6 44.3 11.8
100.0 48.2 42.3 4.2
100.0 86.0 6.0 2.0
100.0 47.9 38.4 9.3
100.0 17.0 47.0 31.0
100.0 15.2 40.0 40.5
100.0 15.0 23.1 57.6
100.0 12.7 24.7 58.2
100.0 10.2 20.9 63.8
100.0 9.4 12.5 73.8
80.0 49.3 23.1 3.0
47

49. 11
mmHg
JNC 7 2.4 6
6-9
48

50. 6-10 6-11 6-1
6-9
( )/ 100
( 100 )
100
6-10
1.
49

51. 2.
3.
1.
2.
3.
1.
2.
3.
50

52. 1.
2.
6-11
1 2
2000 5
1 1 1/5 6
1/5 1 3
1 5
2 1/2 12
2 10
2/5 2
51

53. 6-1
220 / 60 80%
10 mmHg
JNC 7 30
52

54. 210
0.6 g/kg
30 cc
30 cc 720 cc 300 cc 200 cc
60 cc 60 cc
30 cc 6-12
6-12 30 cc cc.
30 cc (cc.)
16.50% 180
15% 200
15% 200
10.50% 290
34% 90
28.50% 100
35% 90
54% 60
19.50% 150
4.50% 670
53

55. withdrawal syndrome
1.6
54

56. 55

57. JNC 7
140/90 mmHg
140/90 mmHg
130/80 mmHg
7-1
56

58. 7-1
(<140/90
mmHg
<130/80mmHg
(
(
160 mmHg
140-159 mmHg (ACEI,
90-99 mmHg) ARB, diuretics, -
thiazide blockers, CCB
thiazide
ACEI ARB -
ACEI, ARB, -blockers, blockers, CCB
CCB
140-159 mmHg 90~99 mmHg
57

59. 160 mmHg 100 mmHg
angiotensin converting enzyme inhibitor,
ACEI angiotensin receptor blocker, ARB
-blocker calcium
channel blocker, CCB thiazide
7-1 7-2
7-3
7-1
Class- Drug (Trade Name)- ( ) Usual Dose Range Daily
mg/d- Frequency-
Thiazide diuretics Chlorothiazide (Diuril) 125-500 1
Chlorthalidone (generic) 12.5-25 1
Hydrochlorothiazide(Microzide, 12.5-50 1
HydroDIURIL)+
Polythiazide(Renese) 2-4 1
Indapamide(Lozol, Natrilix)+ 1.25-2.5 1
Metolazone(Mykrox) 0.5-1.0 1
Metolazone(Zaroxolyn) 2.5-5 1
Loop diuretics Bumetanide(Bumex, Burinex)+ 0.5-2 2
Furosemide(Lasix)+ 20-80 2
Torsemide(Demadex)+ 2.5-10 1
58

60. Potassium- Amiloride(Midamor)+ 5-10 1-2
sparing diuretics
Triamterene(Dyrenium) 50-100 1-2
Aldosterone- Eplerenone(Inspra) 50-100 1-2
receptor blockers
Spironolactone(Aldactone)+ 25-50 1-2
-Blockers Atenolol(Tenormin)+ 25-100 1
Betaxolol(Kerlone)+ 5-20 1
Bisoprolol(Zebeta)+ 2.5-10 1
Metoprolol(Lopressor, Betaloc)+ 50-100 1-2
Metoprolol extended release 50-100 1
(Toprol XL)
Nadolol(Corgard)+ 40-120 1
Propranolol(inderal)+ 40-160 2
Propranolol long-acting(InderalLA)+ 60-180 1
Timolol(Blocadren)+ 20-40 2
-Blockers with Acebutolol(Sectral)+ 200-800 2
intrinsic
sympathomimetic
activity
Penbutolol(Levatol) 10-40 1
Pindolol(generic) 10-40 2
Combined Carvedilol(Coreg, Dilatrend) 12.5-50 2
-and -blockers
Labetalol(Normodyne, Trandate)+ 200-800 2
59

61. ACE inhibitors Benazepril(Lotensin)+ 10-40 1-2
Captopril(Capoten)+ 25-100 2
Enalapril(Vasotec, Renitec)+ 2.5-40 1-2
Fosinopril(Monopril) 10-40 1
Lisinopril(Prinivil, Zestril)+ 10-40 1
Moexipril(Univasc) 7.5-30 1
Perindopril(Aceon) 4-8 1-2
Quinapril(Accupril) 10-40 1
Ramipril(Altace, Tritace) 2.5-20 1
Trandolapril(Mavik) 1-4 1
Angiotensin P Candesartan(Atacand Blopress) 8-32 1
receptor blocker Eprosartan(Tevetan) 400-800 1-2
Irbesartan(Aprovel) 150-300 1
Losartan(Cozaar) 25-100 1-2
Olmesartan(Benicar) 20-40 1
Telmisartan(Micardis) 20-80 1
Valsartan(Diovan) 80-320 1
Calcium channel Diltiazem extened release( 180-420 1
blockers- Cardizem CD, Dilacor XR,
non- Tiazact)+
dihydropyridines
Diltiazem extended release( 120-540 1
Cardizem LA)
Verapamil immediate release( 80-320 2
Calan, Isoptin)+
Verapamil long-acting(Calan 120-360 1-2
SR, Isoptin SR)+
Verapamil-coer(Covera HS, 120-360 1
Verelan PM)
60

62. Calcium channel Amlodipine(Norvasc) 2.5-10 1
blockers- Felodipine(Plendil) 2.5-20 1
dihydropyridines
Isradipine(Dynacirc CR) 2.5-10 2
Nicardipine sustained release 60-120 2
(Cardene SR)
Nifedipine long-acting (Adalat 30-60 1
CC, Procardia XL)
Nisoldipine(Sular) 10-40 1
-Blockers Doxazosin(Cardura, Doxaben) 1-16 1
Prazosin(Minipress) 2-20 2-3
Terazosin(Hytrin) 1-20 1-2
Central - Clonidine(Catapres) 0.1-0.8 2
2
agonists and Clonidine patch(Catapres TTS) 0.1-0.3 1 weekly
other centrally
acting drugs
Methyldopa(Aldomet) 250-1000 2
Reserpine(generic) 0.05-0.25 1#
Guanfacine(generic) 0.5-2 1
Direct Hydralazine(Apresoline)+ 25-100 2
vasodilators Minoxidil(Loniten)+ 2.5-80 1-2
Abbreviation: ACE, angiotensin-converting enzyme.
* Dosages may vary from those listed in the Physicians Desk Reference. Which
may be consulted for additional information.
Are now or will soon become available in generic preparations.
+
A 0-1 mg dose may be given every other day to achieve this dosage.
#
61

63. 7-2
Thiazides
Loop diuretics thiazides
Potassium- ACE NSAID
sparing agents
Spironolactone
Triamterene
Amiloride
( )
Acebutolol
Atenolol
Betaxolol
Bisoprolol
Carteolol HDL (pindolol
Metoprolol acetbutolol )
Pindolol
Propranolol
Timolol
( -1- )
Prazosin (first doseeffect)
Terazosin
62

64. ( )
Labetalol
Vasodilators
Hydralazine Antinuclear antibody(ANA)
Minoxidil
Captopril
Cilazapril
Enalapril
Fosinopril
Lisinopril
Quinapril
Candesartan
Eprosartan
Irbesartan
63

65. Losartan ( )
Olmesartan ( )
Telmisartan
Valsartan (
)
Verapamil
Diltiazem
Nifedipine
Nicardipine
Felodipine
Amlodipine
Isradipine
Clonidine
-
Methyldopa clonidine
catecholamine
Guanabenz
Guanfacine
64

66. Guanadrel
sulfate
Guanethidine
monosulfate
Rauwolfia
alkaloids
Reserpine
7-3
Cholestyramine colestipol Aldosterone
thiazides
furosemide
NSAID( aspirin
)
NSAID - Cimetidine diltiazem verapamil
Rifampin phenobarbital
Quinidine reserpine
65

67. theophylline lidocaine
chlorpro-mazine
(
phenylpropanolamine
ephedrine pseudoephedrine
) epine-phrine
( receptor
)
-
( )
ACE NSAID( aspirin ) ACE
NSAID
( )
ACE
(bioavailability)
66

68. NSAID( aspirin )
( NSAID
)
Cimetidine Verapamil digoxin
carbamazepine
rifampin verapamil diltiazem
carbamazepine diltiazem
verapamil phenobarbital Verapamil
phenytoin verapamil prazosin theophylline
Cyclosporine
guanethidine
ephedrine amphetamine clonidine
Methyldopa
phenothiazine
Monoamine oxidase
inhibitors (MAO )
tyramine
67

69. norepinephrine
reserpine
guanethidine
clonidine guanabenz
thiazide
thiazide
()
thiazide
Treatment to Prevent
Heart Attack trial Anti-Hypertension and Lipid-lowering trial thiazide
The Second Australian National Blood Pressure trial
ACE
68

70. thiazide
thiazide ACEI
ARB -blocker CCB
()
7-4
7-4
ACE
69

71. ()
20/10 mmHg
7-5
7-5
Combination Type Fixed-Dose Combination, mg* Trade Name
ACE inhibitors and Amlodipine/benazepril hydrochloride(2.5/10,5/10,5 Lotrel
CCBs /20,10/20)
Enalapril maleate/felodipine (5/5) Lexxel
Trandolapril/verapamil (2/180,1/240,2/240,4/240) Tarka
ACE inhibitors and Benazepril/hydrochlorothiazide (5/6.25,10/12.5,50/ Lotensin HCT
diuretics 15,50/25)
Captopril/hydrochlorothiazide (25/15,25/25,50/15, Capozide
50/25)
Enalapril maleate/hydrochlorothiazide (5/12.5,10/25) Vaseretic
Lisinopril/hydrochlorothiazide (5/12.5,20/12.5,20/25) Prinzide
Moexipril HCI/hydrochlorothiazide (7.5/12.5,15/25) Uniretic
Quinapril HCI/hydrochlorothiazide (10/12.5,20/12.5, Accuretic
20/25)
ARBs and diuretics Candesartan cilexetil/hydrochlorothiazide (16/12.5,32 Atacand HCT
/12.5)
Eposartan cilexetil/hydrochlorothiazide (600/12.5,600 Teveten HCT
70

72. /25)
Irbesartan/hydrochlorothiazide (75/12.5,150/12.5,300 Avalide
/12.5)
Losartan potassium/hydrochlorothiazide (50/12.5,100 Hyzaar
/25)
Telmisartan/hydrochlorothiazide (40/12.5,80/12.5) Micardis HCT
Valsartan/hydrochlorothiazide (80/12.5,160/12.5) Diovan HCT
-Blockers and Atenolol/chlorthalidone (50/25,100/25) Tenoreic
diuretics Bisoprolol fumarate/hydrochlorothiazide (2.5/6.25,5/ Ziac
6.2510/6.25)
Propranolol tartrate/hydrochlorothiazide (40/25,80/25) Inderide
Metoprolol tartrate/hydrochlorothiazide (50/25,100/25) Lopressor HCT
Nadolol/bendrofluthiazide (40/5,80/5) Cozide
Timolol maleate/hydrochlorothiazide (10/25) Timolide
Centrally acting Amiloride HCI/hydrochlorothiazide (250/15,250/25, Aldoril
grug and diuretic 500/30,500/50)
Reserpine/chlorothiazide (0.125/250,0.25/500) Diupres
Reserpine/hydrochlothiazide Hydropres
Diuretic and diuretic Amiloride HCI/hydrochlorothiazide (5/50) Moduretic
Spironolactone/hydrochlorothiazide (25/25,50/50) Aldactone
Triamterene/hydrochlorothiazide (37.5/25,50/25,75 Dyazide.
/50) Maxzide
Abbreviations:ACE angiotensin-converting enzyme:ARB, angiotensin-receptor
blocker,CCB,calcium channel blocker,HCI,hydrochloride,HCT,hydrochlorothiazide,LA, long-
acting.
* Some drug combinations are available in multiple fixed doses. Each drug dose is reported
in milligrams.
71

73. ()
(serum potassium K)
(creatinine Cr)
Aspirin
7-6
72

74. 7-6
(1)
(2)
a.
b.
c.
d.
NSAID
(3)
(4)
(5)
30 cc
73

75. 140 mmHg 90 mmHg
guanethidine guanadrel -1 labetalol
95
(Doppler)
74

76. ACE
2 3
75

77. (1) (2) (3)
(4)
140/90 mmHg
30 mmHg 15 mmHg
140/90 mmHg
6 mg/dL
1.
ACE
methyldopa
ACE
2.
76

78. 100 mmHg
methyldopa
hydralazine - -
hydralazine
furosemide
nifedipine clonidine
77

79. >220 mmHg >120
mmHg
220 mmHg 120
mmHg
10 15% ACE
thiazide
ACE
ACE
78

80. ACE
loop
ACE
hydralazine minoxidil
79

81. ACE
ACE
130/80 mmHg
-1
/ ACE
- -
phenylpropanolamine
guanethidine reserpine
80

82. -
agonist
total cholesterol , TC
high-density lipoprotein cholesterol, HDL-C
low-density lipoprotein cholesterol, LDL-C
triglyceride, TG 8-
1
Thiazide loop LDL-C
HDL-C
intrinsic sympathomimetic effect
labetalol
-1-
LDL-C
ACE
81

83. 8-1
2 TC/HDL-C
=( 5 HDL-C
) 40 mg/dL
X
V
200 mg/dL 200 mg/dL
TC
240 mg/dL X
X 240 mg/dL
V X
130 mg/dL 130 mg/dL
LDL-
C 160 mg/dL
X X
160 mg/dL
TG 200 mg/dL
(
200
(
X V mg/dL
TC/HDL-C 5
(87/4/1)
HDL-C 40
)
mg/dL)
160
X X
TC 200 mg/dL mg/dL
(87/7/1)
100
LDL-C 130
X X mg/dL
mg/dL
(87/7/1)
TG 200 mg/dL
150
(
X V mg/dL
TC/HDL-C 5
(87/7/1)
HDL-C 40
mg/dL)
1000 mg/dL (87/4/1)
1.
(1)
(2)
(3)
2.
(1)
(2)
(3) 70%
3.
1. 2. 3. 45 4. 5. 55
6.
82

84. Thiazide
( :allopurinol)
( probenecid)
thiazide
(1) 60 ml/min/1.73 m2
( 1.5 mg/dL 1.3 mg/dL) (2)
300 mg 200
mg/gm
130/80 mmHg
ACE
35
ACE
30 ml/min/1.73 m2 (
2.5 3.0 mg/dL) loop
83

85. ( 30)
(
90 80 BMI 24) (
110 mg/dL) 130/85 mmHg (
150 mg/dL) ( 40 mg/dL
50 mg/dL)
10 mmHg
( - )
(norepinephrine)
84

86. - ( phentolamine)
(
)
(Cyclosporine)
50 70
labetalol clonidine
diltiazem nicardipine verapamil
85

87. ( 7-2)
Thiazide
( )
Raynaud
-
Thiazide
ACE
ACE
(angioedema) 5 mEq/L
86

88. ( )
( 120-139 mmHg 80-89 mmHg)
JNC 7
5 mmHg
14% 9% 7%
(1)
(2)
(3) ( )
(4)
87

89. (5)
(6)
(1) ( )
(
)
88

90. (2)
( )
( )
( )
89

91. 90

92. 1. American Diabetes Association. Treatment of hypertension in adults
with diabetes. Diabetes Care. 2003;26(suppl 1):S80-S82.
2. Black HR, Elliott WJ, Grandits G, et al. Principal results of the
Controlled Onset Verapamil Investigation of Cardiovascular End
Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
3. Blood Pressure Lowering Treatment Trialists Collaboration. Effects
of ACE inhibitors, calcium antagonists, and other blood-pressure-
lowering drugs: results of prospectively designed overviews of
randomized trials. Lancet. 2000;256:1955-1964.
4. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on
renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy. N Engl J Med. 2001;345:861-869.
5. Chien KL, Sung FC, Hsu HC, Su TC, Lee YT. Left ventricular mass
and correlated atherosclerotic risk factors in young adolescents:
report from Chin-Shan community cardiovascular study in Taiwan.
Atherosclerosis. 2001;155:431-437.
6. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure. National Heart, Lung, and Blood Institute; National High
Blood Pressure Education Program Coordinating Committee.
Seventh report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure.
Hypertension. 2003;42:1206-1252.
7. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and
Blood Institute Joint National Committee on Prevention, Detection,
91

93. Evaluation, and Treatment of High Blood Pressure; National High
Blood Pressure Education Program Coordinating Committee. The
Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure: the
JNC 7 report. JAMA. 2003;289:2560-2572.
8. Dahlof B, Devereux RB, Kjeldsen SE. et al. Cardiovascular morbidity
and mortality in the Losartan Intervention For Endpoint Reduction in
Hypertension Study (LIFE). Lancet. 2002;359:995-1003.
9. Guidelines Subcommittee: 1999 World Health Organization-
International Society of Hypertension guidelines for the management
of hypertension. J Hypertens. 1999;17:151-183.
10. Guidelines Committee. 2003 European Society of Hypertension-
European Society of Cardiology guidelines for the management of
arterial hypertension. J Hypertens. 2003;21:1011-1053.
11. Kjeldsen SE, Erdine S, Farsang C, Sleight P, Mancia G; 1999
WHO/ISH Hypertension Guidelines subcommittee. 1999 WHO/ISH
Hypertension Guidelines--highlights & ESH update. J Hypertens.
2002;20:153-155.
12. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific
relevance of usual blood pressure to vascular mortaility. Lancet.
2002;360:1903-1913.
13. Lee YT, Lin RS, Sung FC, Yang CY, Chien KL, Chen WJ, Su TC, Hsu
HC, Huang YC. Chin-Shan Community Cardiovascular Cohort in
Taiwan-baseline data and five-year follow-up morbidity and mortality.
J Clin Epidemiol. 2000;53:838-846.
14. Lewis WJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of
the angiotensin-receptor antagonist irbesartan in patients with
92

94. nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-
860.
15. National Kidney Foundation Guideline. K/DOQI clinical practice
guidelines for chronic kidney disease: kidney Disease Outcome
Quality Initiative. Am J Kidney Dis. 2002;39(suppl 2):S1-S246.
16. National Cholesterol Education Program. Third Report of the National
Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
17. National High Blood Pressure Education Program. Report of the
National High Blood Pressure Education Program Working Group on
high blood pressure in pregnancy. Am J Obstet Gynecol.
2000;183:S1-S22.
18. National High Blood Pressure Education Program Working Group on
Hypertension Control in Children and Adolescents. Update on the
1987 Task Force Report on high blood pressure in children and
adolescents. Pediatrics. 1996;98:649-658.
19. Pan WH, Chang HY, Yeh WT, Hsiao SY, Hung YT. Prevalence,
awareness, treatment and control of hypertension in Taiwan: results
of Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996. J
Hum Hypertens. 2001;15:793-798.
20. Pitt B, Remme W, Zannad F. et al. Eplerenone a selective
aldosterone blocker, in patients with left ventricular dysfunction after
myocardial infarction. N Engl J Med. 2003;348:1309-1321.
21. Sacks FM, Svetkey LP, Vollmer WM, et al, for the DASH-Sodium
Collaborative Research Group. Effects on blood pressure of reduced
dietary sodium and the Dietary Approaches to Stop Hypertension
93

95. (DASH) diet. N Engl J Med. 2001;344;3-10.
22. Su TC, Jeng JS, Chien KL, Sung FC, Hsu HC, Lee YT. Hypertension
status is the major determinant of carotid atherosclerosis: a
community-based study in Taiwan. Stroke. 2001;32:2265-2271.
23. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative
Research Group. Major outcomes in high-risk hypertensive patients
randomized to angio-tensin-converting enzyme inhibitor or calcium
channel blocker vs diuretic. JAMA. 2002;288:2981-2997.
24. The Heart Outcomes Prevention Evaluation Study Investigators.
Effects of an angiotensin-converting-enzyme inhibitor. ramipril, on
cardiovascular events in high-risk patients. N Engl J Med.
2000;342:145-153.
25 The Capricorn Investigators. Effect of carvedilol on outcome after
myocardial infarction in patients with left-ventricular dysfunction: the
CAPRICORN randomized trial. Lancet. 2001;357:1385-1390.
26. Torng PL, Su TC, Sung FC, Chien KL, Huang SC, Chow SN, Lee YT.
Effects of menopause on intraindividual changes in serum lipids,
blood pressure, and body weight--the Chin-Shan Community
Cardiovascular Cohort study. Atherosclerosis. 2002; 161:409-415.
27. UK Prospective Diabetes Study Group. Tight blood pressure control
and risk of macrovascular and microvascular complications in type 2
diabetes. UKPDS 38. BMJ 1998;317:703-713.
28. Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of
progression to hypertension in non-hypertensive participants in The
Framingham Heart Study. Lancet. 2001;358:1682-1686.
29. Verdecchia P. Prognostic value of ambulatory blood pressure.
Hypertension. 2000;35:844-851.
94

96. 30. Whelton PK, He J, Appel LJ, et al. Primary prevention of
hypertension: clinical and public health advisory from The National
High Blood Pressure Education Program. JAMA. 2002;288;1882-
1888.
31. Wang TD, Chen WJ, Chien KL, Seh-Yi Su SS, Hsu HC, Chen MF,
Liau CS, Lee YT. Efficacy of cholesterol levels and ratios in predicting
future coronary heart disease in a Chinese population. Am J Cardiol.
2001;88:737-743.
32. Wing LMH, Reid CM, Ryan P, et al, for Second Australian National
Blood Pressure Study Group. A comparison of outcomes with
angiotensin-converting-enzyme inhibitors and diuretics for
hypertension in the elderly. N Engl J Med. 2003;348:583-592.
33. World Health Organization, International Society of Hypertension
Writing Group. 2003 World Health Organization (WHO)/International
Society of Hypertension (ISH) statement on management of
hypertension. J Hypertens. 2003;21:1983-1992.
34. Wright JT Jr. Agodoa L, Contreras G. et al. Successful blood
pressure control in the African American Study of Kidney Disease
and Hypertension. Arch Intern Med. 2002;162:1636-1643.
35.
2003
95

97. 408 503 5
http://health91.bhp.doh.gov.tw/1-4.htm
93 3
GPN 1009300818
ISBN 957-01-6950-8
96